Replies to post #326032 on Amarin Corp Plc (AMRN)

[dukesking]

An accurate and beautifully stated summary of events. Well said.

[marjac]

Extremely well articulated, Bird. I may "borrow" your concluding paragraph for the Rule 60 Brief!

[Webster_iam]

Bird and Marjac, Correct me If I'm wrong, but I'm not sure Bird's final conclusion is entirely accurate. I believe the FDA reneged on its promise, allowing Amarin to sell Vascepa through the Reduce-It trial completion, if the Marine Trial was a success, which it was. Their reasoning for reneging: Emerging data showing Triglyceride lowering alone does not equal event reduction, so they were disallowing another TG lowering drug from being approved. Amarin was always going to have to prove event reduction, regardless of Triglyceride lowering benefits. However, instead of selling Vascepa through the 5 year Reduce-it trial for TG's >500, they (WE) had wait it out. All the while, scheduling additional stock offerings. With that being said, the FDA approving "another" TG lowering drug for 500 and above TG's, in the form of generic V is a bit bewildering.

Webster

[rosemountbomber]

But it was only the Marine patents that were invalidated right? I realize that it opened the door for them to infringe, but I think even judge Du warned about infringing on R-I patents.

[DAR53]

BBI, I could not agree with you more. Very well articulated.